|1.||Prinz, Walter: 1 article (09/2008)|
|2.||Baudler, Monika: 1 article (09/2008)|
|3.||Figala, Volker: 1 article (09/2008)|
|4.||Herrmann, Michael: 1 article (09/2008)|
|5.||Dullweber, Frank: 1 article (09/2008)|
|6.||Klein, Thomas: 1 article (09/2008)|
|7.||Brehm, Christoph: 1 article (09/2008)|
|8.||Germann, Paul-Georg: 1 article (07/2003)|
|9.||Häfner, Dietrich: 1 article (07/2003)|
|10.||Wollin, Lutz: 1 article (07/2003)|
|1.||Body Weight (Weight, Body)
11/01/1998 - "Eltenac (50 mg/ml) was administered IV at a dosage of 0.5 mg/kg of body weight every 24 hours for days 0 through 4. On days 0 and 4, blood samples were collected before, then periodically for 8 hours after eltanac administration. "
03/01/1997 - "To titrate a clinically effective eltenac dosage (0.1, 0.5, and 1.0 mg/kg of body weight), compared with vehicle only, and to compare efficacy of the most effective eltenac dosage with that of 1.1 mg of flunixin meglumine/kg. 40 healthy horses, ranked after model induction on the basis of lameness severity, were randomly assigned to 5 treatment groups, with 4 replicates of 10 horses each. "
01/01/1997 - "Local NSAID gel (eltenac) in the treatment of osteoarthritis of the knee. "
01/01/1997 - "In a randomized, double blind, multicentre study with 4 weeks follow-up of 290 patients with osteoarthritis of the knee joint, a topical NSAID (eltenac) was compared with oral diclofenac and placebo. "
06/01/1991 - "Swelling was assessed by measuring the diameter of the external preputial fold using two methods: callipers and a rating scale of 0 to 3. Additionally, photographs were taken on days 1, 2 and 4. Compared with the placebo treatment, eltenac inhibited pain and swelling significantly. "
06/01/1991 - "Compared with the placebo treatment, eltenac produced significant pain relief after a single i.v. injection for a period of 24 h. "
03/01/1997 - "Thus, a dose-response plateau for eltenac was reached at 0.5 mg/kg. Comparison with flunixin meglumine at a dosage of 1.1 mg/kg did not indicate significant differences between the 2 treatment groups at the pivotal time of 96 hours for carpal circumference, carpal flexion angle, stride length, carpal hyperthermia, and signs of carpal pain. "
|4.||Acute Lung Injury
|1.||flunixin meglumine (Banamine)
|2.||Diclofenac (SR 38)
|4.||Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
|5.||Dihydrotachysterol (AT 10)
|6.||Non-Steroidal Anti-Inflammatory Agents (NSAIDs)